| Dr Douglas A Zale, MD | |
|
711 S Calumet Rd, Chesterton, IN 46304-3220 | |
| (219) 926-1001 | |
| (219) 929-1989 |
| Full Name | Dr Douglas A Zale |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 38 Years |
| Location | 711 S Calumet Rd, Chesterton, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982601449 | NPI | - | NPPES |
| 100207650 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 01036095A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Health - Porter | Valparaiso, IN | Hospital |
| Entity Name | Douglas A Zale Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164591848 PECOS PAC ID: 9234128018 Enrollment ID: O20060501000270 |
News Archive
The results of two separate research studies taking place at Children's Mercy Hospitals and Clinics will help physicians use genetic testing to prevent complications, and ease the worry of new parents by predicting in advance which newborns may require readmission to the hospital shortly after birth. The studies also will help physicians identify which of their young patients are likely to respond well - or not - to steroid therapy for asthma.
GenSpera, Inc. announced that its patent application, entitled "Tumor Activated Prodrugs," has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera's second anti-cancer drug in development.
The technology, developed by researchers at Imperial College London and The University of Hong Kong, can be used to measure hormones that affect fertility, sexual development and menstruation more quickly and cheaply than current methods.
The article presents the results of the diagnostic protocol for Covid-19 that Libertario Demi developed with a dozen Italian clinical teams that are working very hard in emergency settings.
The Illinois General Assembly late yesterday passed—with overwhelming bipartisan support—an Angel Tax Credit that incentivizes early-stage investment in Illinois technology companies. The Governor, whose office worked hard to pass the credit, is expected to sign the bill (SB 2093) or a second measure (SB 3710) with an identical Angel Tax Credit sent to the Senate yesterday by the House.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas A Zale, MD 711 S Calumet Rd, Chesterton, IN 46304-3220 Ph: (219) 926-1001 | Dr Douglas A Zale, MD 711 S Calumet Rd, Chesterton, IN 46304-3220 Ph: (219) 926-1001 |
News Archive
The results of two separate research studies taking place at Children's Mercy Hospitals and Clinics will help physicians use genetic testing to prevent complications, and ease the worry of new parents by predicting in advance which newborns may require readmission to the hospital shortly after birth. The studies also will help physicians identify which of their young patients are likely to respond well - or not - to steroid therapy for asthma.
GenSpera, Inc. announced that its patent application, entitled "Tumor Activated Prodrugs," has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera's second anti-cancer drug in development.
The technology, developed by researchers at Imperial College London and The University of Hong Kong, can be used to measure hormones that affect fertility, sexual development and menstruation more quickly and cheaply than current methods.
The article presents the results of the diagnostic protocol for Covid-19 that Libertario Demi developed with a dozen Italian clinical teams that are working very hard in emergency settings.
The Illinois General Assembly late yesterday passed—with overwhelming bipartisan support—an Angel Tax Credit that incentivizes early-stage investment in Illinois technology companies. The Governor, whose office worked hard to pass the credit, is expected to sign the bill (SB 2093) or a second measure (SB 3710) with an identical Angel Tax Credit sent to the Senate yesterday by the House.
› Verified 6 days ago